ARGX ArGEN-X SE

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences



August 28, 2024



Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September:

  • 2024 Wells Fargo Healthcare Conference. Fireside chat on Wednesday, September 4, 2024 at 1:30 p.m. ET in Boston, MA.



  • Morgan Stanley 22nd Annual Global Healthcare Conference. Fireside chat on Thursday, September 5, 2024 at 4:50 p.m. ET in New York, NY.



  • Baird 2024 Global Healthcare Conference. Fireside chat on Tuesday, September 10, 2024 at 9:40 a.m. ET in New York, NY.



Additional information regarding these events will be available on the Investors section of the argenx website at .

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on , , , , and .

For further information, please contact:

Media:

Ben Petok

Investors:

Alexandra Roy (US)

Lynn Elton (EU)



EN
28/08/2024

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE...

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology co...

September 19, 2024 1 EN
Free Trial
ARGX ARGEN-X SE

Argen X SE: 1 director

A director at Argen X SE sold 924 shares at 495.250EUR and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

09/11/24 September 11, 2024 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference. Fireside chat on Wednesday, September 4, 2024 at 1:30 p.m. ET in Boston, MA.Morgan Stanley 22nd Annual Global Healthcare Conference. Fireside chat on Thursday, September 5, 2024 at 4:50 p.m....

August 28, 2024 1 EN
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Thomas Couvreur
  • Thomas Vranken
ARGX ARGEN-X SE
HYL HYLORIS PHARMACEUTICALS
08/19/24 August 19, 2024 1 EN
Thomas Vranken
  • Thomas Vranken
ARGX ARGEN-X SE

argenx Consistently moving into earlier-line MG (Model Update)

Following argenx' recent R&D Day and 1H24 results, we strengthen our confidence in the company's ability to enter into earlier lines of treatment for myasthenia gravis. We raise our FY24 revenue estimates and factor into account ongoing development efforts to enter seronegative gMG and ocular MG patients as well. As such, we adjust our TP from € 492 to € 530, however adopt an Accumulate rating (previously Buy) to reflect fewer major catalysts for the remainder of 2024.

08/19/24 August 19, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch